Isolation and functional characterization of peptide agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor suppressor activity.

PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens. PTPRJ negatively interferes with mitogenic signals originating from several oncogenic receptor tyrosine kinases, including HGFR, PDGFR, RET, and VEGFR-2. Here we report the isolation and characterization of peptides from a random peptide phage display library that bind and activate PTPRJ. These agonist peptides, which are able to both circularize and form dimers in acqueous solution, were assayed for their biochemical and biological activity on both human cancer cells and primary endothelial cells (HeLa and HUVEC, respectively). Our results demonstrate that binding of PTPRJ-interacting peptides to cell cultures dramatically reduces the extent of both MAPK phosphorylation and total phosphotyrosine levels; conversely, they induce a significant increase of the cell cycle inhibitor p27(Kip1). Moreover, PTPRJ agonist peptides both reduce proliferation and trigger apoptosis of treated cells. Our data indicate that peptide agonists of PTPRJ positively modulate the PTPRJ activity and may lead to novel targeted anticancer therapies.

[1]  Ronald W. Barrett,et al.  Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin , 1996, Science.

[2]  G. Meijer,et al.  LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12–21 , 2003, Oncogene.

[3]  C. Dobson,et al.  Hydrodynamic radii of native and denatured proteins measured by pulse field gradient NMR techniques. , 1999, Biochemistry.

[4]  B. Vanhaesebroeck,et al.  Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148 , 2011, Molecular biology of the cell.

[5]  C. Hellberg,et al.  Protein-tyrosine phosphatases and cancer , 2006, Nature Reviews Cancer.

[6]  L. Castagnoli,et al.  Tumor Suppressor Density-enhanced Phosphatase-1 (DEP-1) Inhibits the RAS Pathway by Direct Dephosphorylation of ERK1/2 Kinases* , 2009, The Journal of Biological Chemistry.

[7]  C. Croce,et al.  Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo. , 2004, Carcinogenesis.

[8]  G. Viglietto,et al.  An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. , 2003, Cancer research.

[9]  Marco Pierini,et al.  “Quasi flexible” automatic docking processing for studying stereoselective recognition mechanisms, part 2: Prediction of ΔΔG of complexation and 1H‐NMR NOE correlation , 2007, J. Comput. Chem..

[10]  C. Croce,et al.  Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. , 2006, DNA and cell biology.

[11]  Bernd Meyer,et al.  Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.

[12]  I. Prior,et al.  Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells. , 2010, The Biochemical journal.

[13]  Wadih Arap,et al.  Biopanning and rapid analysis of selective interactive ligands , 2001, Nature Medicine.

[14]  R. Vilella,et al.  Site-selective Dephosphorylation of the Platelet-derived Growth Factor β-Receptor by the Receptor-like Protein-tyrosine Phosphatase DEP-1* , 2000, The Journal of Biological Chemistry.

[15]  K. Wüthrich.  NMR of proteins and nucleic acids , 1988 .

[16]  R. Roberts,et al.  The tyrosine phosphatase CD148 interacts with the p85 regulatory subunit of phosphoinositide 3-kinase. , 2008, The Biochemical journal.

[17]  A. Weiss,et al.  Structurally distinct phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling. , 2008, Immunity.

[18]  N. Tonks,et al.  Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Michael V. Doyle,et al.  Semirational design of a potent, artificial agonist of fibroblast growth factor receptors , 1999, Nature Biotechnology.

[20]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[21]  A. Östman,et al.  An extracellular ligand increases the specific activity of the receptor-like protein tyrosine phosphatase DEP-1 , 2001, Oncogene.

[22]  G. Viglietto,et al.  The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. , 2006, Cancer research.

[23]  F. Gasparrini,et al.  A quasi-flexible automatic docking processing for studying stereoselective recognition mechanisms. Part I. Protocol validation , 2000, J. Comput. Chem..

[24]  Joanna M. Sasin,et al.  Protein Tyrosine Phosphatases in the Human Genome , 2004, Cell.

[25]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[26]  G. Viglietto,et al.  Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. , 1997, Experimental cell research.

[27]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[28]  S. Lipkowitz,et al.  The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. , 1996, Cancer research.

[29]  Cestmir Vlcek,et al.  Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers , 2002, Nature Genetics.

[30]  R. Roberts,et al.  The tyrosine phosphatase CD 148 interacts with the p 85 regulatory subunit of phosphoinositide 3-kinase , 2008 .

[31]  Charles S. Johnson,et al.  An Improved Diffusion-Ordered Spectroscopy Experiment Incorporating Bipolar-Gradient Pulses , 1995 .

[32]  Kit S Lam,et al.  Therapeutic cancer targeting peptides. , 2002, Biopolymers.

[33]  M. Corada,et al.  Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, β-catenin, and the phosphatase DEP-1/CD148 , 2003, The Journal of cell biology.

[34]  S. Gallinger,et al.  Problems of Delivery of Monoclonal Antibodies , 1995, Clinical pharmacokinetics.

[35]  Stefano Alcaro,et al.  A “quasi‐flexible” automatic docking processing for studying stereoselective recognition mechanisms. Part I. Protocol validation , 2000, J. Comput. Chem..

[36]  William J. Dower,et al.  Toward cell–targeting gene therapy vectors: Selection of cell–binding peptides from random peptide–presenting phage libraries , 1996, Nature Medicine.

[37]  V. Quaranta,et al.  Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase , 2012, Proceedings of the National Academy of Sciences.

[38]  G. Viglietto,et al.  Rat Protein Tyrosine Phosphatase η Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1 , 2000, Molecular and Cellular Biology.

[39]  S. Tangye,et al.  Protein Tyrosine Phosphatase CD148-Mediated Inhibition of T-Cell Receptor Signal Transduction Is Associated with Reduced LAT and Phospholipase Cγ1 Phosphorylation , 2001, Molecular and Cellular Biology.

[40]  S. Tangye,et al.  Protein Tyrosine Phosphatase CD148-Mediated Inhibition of T-Cell Receptor Signal Transduction Is Associated with Reduced LAT and Phospholipase Cγ1 Phosphorylation , 2001, Molecular and Cellular Biology.

[41]  N. Tonks,et al.  Hepatocyte Growth Factor Receptor Tyrosine Kinase Met Is a Substrate of the Receptor Protein-tyrosine Phosphatase DEP-1* , 2003, The Journal of Biological Chemistry.

[42]  Y. Yazaki,et al.  Molecular cloning, characterization, and chromosomal localization of a novel protein-tyrosine phosphatase, HPTP eta. , 1994, Blood.

[43]  Keiko Takahashi,et al.  A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis. , 2006, Blood.

[44]  D. Baccanari,et al.  Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. , 1997, Science.

[45]  J E Dixon,et al.  Protein tyrosine phosphatases. , 1993, Annual review of biochemistry.

[46]  Keiko Takahashi,et al.  A monoclonal antibody against CD 148 , a receptor-like tyrosine phosphatase , inhibits endothelial-cell growth and angiogenesis , 2006 .

[47]  Alex Hajnal,et al.  The C. elegans homolog of the mammalian tumor suppressor Dep-1/Scc1 inhibits EGFR signaling to regulate binary cell fate decisions. , 2005, Genes & development.

[48]  X. Daura,et al.  Peptide Folding: When Simulation Meets Experiment , 1999 .

[49]  A. Fusco,et al.  Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA‐328 , 2013, The FEBS journal.

[50]  B. Neel,et al.  The tyrosine phosphatase Shp2 (PTPN11) in cancer , 2008, Cancer and Metastasis Reviews.

[51]  E. Hudson,et al.  Identification of a Met-Binding Peptide from a Phage Display Library , 2007, Clinical Cancer Research.

[52]  Kathleen M Spring,et al.  New Role for the Protein Tyrosine Phosphatase DEP-1 in Akt Activation and Endothelial Cell Survival , 2008, Molecular and Cellular Biology.

[53]  A. Fusco,et al.  The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis , 2004, Oncogene.

[54]  G. Viglietto,et al.  The eighth fibronectin type III domain of protein tyrosine phosphatase receptor J influences the formation of protein complexes and cell localization. , 2009, Journal of biochemistry.